跳转至内容
Merck
CN

MAB8878

Anti-Cdk1 Antibody, clone A17.1.1

clone A17.1.1, Chemicon®, from mouse

别名:

p34cdc2, CDC2

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
A17.1.1, monoclonal
Application:
IF, IHC, IP, WB, activity assay
Citations:
7
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

A17.1.1, monoclonal

species reactivity

human, Xenopus, mouse, rat, chicken

manufacturer/tradename

Chemicon®

technique(s)

activity assay: suitable, immunofluorescence: suitable, immunohistochemistry: suitable (paraffin), immunoprecipitation (IP): suitable, western blot: suitable

isotype

IgG2a

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

mouse ... Cdk1(12534)

Immunogen

Raised against Xenopus p34cdc2.

Application

Anti-Cdk1 Antibody, clone A17.1.1 is a Mouse Monoclonal Antibody for detection of Cdk1 also known as p34cdc2, CDC2 & has been validated in IF, IP, EA, WB, IHC(P).
Frozen Sections

Immunofluorescence

Immunoprecipitation: (Native/denatured, Protein A; 2μg/mg protein lysate)

Immunohistology (Formalin, 2-4μg/mL for 30 min at RT)

Paraffin Sections (staining requires antigen retrieval).

Western Blotting

Kinase Assay

Optimal working dilutions must be determined by the end user.

p34cdc2, a serine/threonine kinase, is activated by cyclins, presumably by dephosphorylation of tyrosine residues. MAB8878 inhibits the activation of p34cdc2 kinase by cyclins and precipitates an active kinase.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair

Biochem/physiol Actions

Recognizes a 34 kDa protein cdk1, identified as cdk1/p34cdc2 protein kinase (a catalytic subunit of Maturation Promoting Factor). Its epitope maps near the C-terminus of protein and its core is thought to be LGTPNNEV. It shows no cross-reaction with cdk2/p32 and other cyclin dependent kinases (cdks).

Physical form

Format: Purified
Purified immunoglobulin. 0.2 mg/mL in 10 mM PBS, pH 7.4, containing 0.2% BSA and 0.09% Sodium Azide.

Preparation Note

Maintain at 2° to 8°C in undiluted aliquots for up to 12 months from date of receipt.

Analysis Note

Control
POSITIVE CONTROL:

HeLa or NIH3T3 cells. Germinal center in a tonsil or reactive lymph node. Cellular localization is predominantly nuclear, with some cytoplasmic staining.

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

试用我们的 产品选型工具 工具缩小选择范围


存储类别

12 - Non Combustible Liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable



分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Ian M McDonald et al.
The Journal of biological chemistry, 295(8), 2359-2374 (2020-01-04)
The maternal embryonic leucine zipper kinase (MELK) has been implicated in the regulation of cancer cell proliferation. RNAi-mediated MELK depletion impairs growth and causes G2/M arrest in numerous cancers, but the mechanisms underlying these effects are poorly understood. Furthermore, the
E M Alexandrova et al.
Nature, 523(7560), 352-356 (2015-05-27)
Missense mutations in p53 generate aberrant proteins with abrogated tumour suppressor functions that can also acquire oncogenic gain-of-function activities that promote malignant progression, invasion, metastasis and chemoresistance. Mutant p53 (mutp53) proteins undergo massive constitutive stabilization specifically in tumours, which is
Aisling Pierce et al.
Cancer biology & therapy, 14(6), 537-545 (2013-06-14)
PARP inhibitors, both as monotherapy and in combination with cytotoxic drugs, are currently undergoing clinical trials in several different cancer types. In this investigation, we compared the antiproliferative activity of two PARP/putative PARP inhibitors, i.e., olaparib and iniparib, in a



全球贸易项目编号

货号GTIN
MAB887804053252660399